ABRAHAM CHACHOUA, M.D.                  

 click to view this physician's blog

Click here for full CV 

Click here to listen to a radio interview with Dr. Chachoua

EXPERTISE: Lung Cancer


Co-Director Lung Cancer Research Program New York University


Clinical Fellow: Hematology/Oncology, Peter MacCallum Hospital, Melbourne, Australia. Hematology/Oncology Alfred Hospital, Melbourne, Australia

Residencies: Senior Medical Resident; Endocrinology, General Medicine, Oncology Alfred Hospital, Melbourne, Australia. Medical Junior Resident; Cardiology, Intensive Care, Hem/Onc, Rehabilitation, Alfred Hospital, Melbourne, Australia

Medical School: M.D. Monash University, Melbourne, Australia

Intern: ER, Medicine, Surgery Anesthetics, Gastroenterology Prince Henry's Hospital, Melbourne, Australia


Australian Board of Internal Medicine



  • Royal Australasian College of Physicians
  • Eastern Cooperative Oncology Group
  • American Society of Clinical Oncology
  • American Association for Cancer Research




  • Interim Director: Division of Hematology and Medical Oncology, New York University Medical Center, New York, NY


  • Jay and Isabel Fine Associate Professor of Oncology: Division of Hematology and Medical Oncology New York University Medical Center, New York, NY


  • Associate Professor of Medicine: New York University Medical Center, New York, NY


  • Associate Professor: Department of Urology New York University Medical Center, New York, NY
  • (1998-2002) Assistant Professor, Department of Urology, New York University Medical Center, New York, NY
  • (1995-1997)   Director, Oncology, Section of Hematology/Oncology Brooklyn Hospital Center, Brooklyn, NY
  • (1990-2002) Assistant Professor of Clinical Medicine, New York University Medical Center, New York, NY
  • (1988-1990) Research Assistant Professor, New York University Medical Center, New York, NY 
  • (1985-1988) Teaching Assistant, New York University Medical Center, New York, NY 






Completed Support

Grant:  NIH/NCI  (5P30 CA16087-21)      1/1/94-11/30/01
Role:      Co-Investigator / Burakoff (PI)
Title:    Cancer Center Support Core Grant
The major goals of this program is to foster, enhance and coordinate the conduct of oncology research, education and patient activity at NYU Medical Center, and to promote through its programs and specialized shared resources the collaboration and technology transfer intended to more rapidly translate the benefits of research into more effective approaches to cancer. (no cost extension until 2/28/03)

Grant: NIH, NCI (1U01 CA7664)    2/1/98 - 1/31/03
Role:    Co-Investigator / Muggia (PI)    
Title:    Phase I Studies of Anticancer Drug and Gene Therapy
The development of effective anticancer agents and treatment strategies which will be incorporated into multidisciplinary, potentially curative treatment protocols for patients with solid tumors.

Grant: Bristol Myers Squibb   7/1/99 - 6/30/02
Role:   Chachoua (PI)   
Title: Lung Cancer in Women
To test the hypothesis that measurement of molecular biomarkers of carcinogenesis will enhance the sensitivity of CT scan in the early detection of lung cancer in women.

Grant: NIH, NCI - R01 (CA71916)   8/9/96 - 5/31/01
Role:    Co-Investigator / Liebes (PI)
Title: 9 Cis-Retinoic Acid and Interferon- in Kaposi's Sarcoma
Evaluated the efficacy of 9-cis-retinoic acid combined with interferon-1 as novel treatment for HIV associated Kaposi's sarcoma.

Grant: NCI (1 U01CA70075)     9/30/95 - 7/31/99
Role:    Co-Investigator / Friedman-Kien (PI)
Title: NYUMC - AIDS-Related Malignancy Consortium
Developed and executed multicenter Phase I and II clinical treatment trials using novel agents and/or innovative approaches for the treatment of patients with AIDS-associated malignancies and to expand and maintain the established, centralized tissue storage bank containing well characterized patient specimen.

Grant: NCI (1 U01 CA5826)     9/30/92 - 9/29/96
Role: Chachoua (PI)   
Title: Evaluations of Cytokine and Chemotherapy Combinations
Clinical Trials Program:  Implement Phase I clinical trials of combinations of IL-1 alpha and high dose cisplatinum in patients with melanoma; Laboratory Program:  Measured the effects of treatment on specific tumor and host cell functions that will help to reveal mechanisms of response or resistance to the therapeutic protocol.